New combo therapy shows promise for tough lung cancer

NCT ID NCT02823990

First seen Nov 10, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tested a combination of two drugs—TG4010 (a vaccine that helps the immune system attack cancer) and nivolumab (an immunotherapy that removes cancer's brakes on immune cells)—in 13 people with advanced non-small cell lung cancer who had already tried other treatments. The goal was to see if the combination could shrink tumors or stop them from growing. The study was small and early-stage, so results are limited but may guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • UCSF Medical Center-Mount Zion

    San Francisco, California, 94115, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of California San Diego

    San Diego, California, 92103, United States

Conditions

Explore the condition pages connected to this study.